These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10836658)

  • 1. Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism.
    Kaper RF; Norpoth T; Rekers H
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):1-15. PubMed ID: 10836658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 1995 pill scare revisited: anatomy of a non-epidemic.
    Spitzer WO
    Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
    Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bias versus causality: interpreting recent evidence of oral contraceptive studies.
    Spitzer WO
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S43-50. PubMed ID: 9753310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The truth about oral contraceptives and venous thromboembolism.
    Shulman LP; Goldzieher JW
    J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database.
    Farmer RD; Williams TJ; Simpson EL; Nightingale AL
    BMJ; 2000 Aug 19-26; 321(7259):477-9. PubMed ID: 10948026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
    Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptive use before and after the latest pill scare in The Netherlands. Changes in oral contraceptive use and how users change.
    de Vries CS; van den Berg PB; de Jong-van den Berg LT
    Contraception; 1998 Apr; 57(4):247-9. PubMed ID: 9649916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives and cardiovascular outcomes: cause or bias?
    Spitzer WO
    Contraception; 2000 Aug; 62(2 Suppl):3S-9S; discussion 37S-38S. PubMed ID: 11102597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference?
    Lawrenson R; Farmer R
    Contraception; 2000 Aug; 62(2 Suppl):21S-28S; discussion 37S-38S. PubMed ID: 11102599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives.
    Boef AG; Souverein PC; Vandenbroucke JP; van Hylckama Vlieg A; de Boer A; le Cessie S; Dekkers OM
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):317-24. PubMed ID: 26749045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebuilding confidence in oral contraceptives: a new imperative in family planning.
    Spitzer WO
    Br J Clin Pharmacol; 1996 May; 41(5):359-63. PubMed ID: 8735675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential risk of oral contraceptives: the impact of full exposure history.
    Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
    Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of venous thromboembolism in users of postcoital contraceptive pills.
    Vasilakis C; Jick SS; Jick H
    Contraception; 1999 Feb; 59(2):79-83. PubMed ID: 10361621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ; Shelton J
    Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.